chronic management of hypeuricemia in patients with gout.

Feburic is a potent and selective xanthine oxidase inhibitor, thereby reduces the formation of xanthine and uric acid. Feburic is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.

Bioavailability: 49%, plasma protein binding: 99.2%, primarily to albumin; Metabolism: Extensive conjugation via uridine diphosphate glucuronosyltransferases (UGTs) 1A1, 1A3, 1A9, and 2B7 and oxidation via cytochrome P450 (CYP) 1A2, 2C8, and 2C9 as well as non-P450 enzymes. Oxidation leads to formation of active metabolites; Elimination half life: 5-8 hours.

Hypersensitivity to febuxostat or any component of the formulation; Concurrent use with azathioprine and mercaptopurine.

C

Excretion in breast milk unknown/use caution

Liver function abnormalities (5% to 7%), nausea, arthralgia and rash.

Orally, start at 40mg once daily; may be increased to 80 mg once daily if serum uric acid levels of less than 6 mg/dL are not achieved after 2 weeks. Administer with or without meals or antacids.

Renal impairment (severe, CrCl, 15 to 29 mL/min): Limit dose to 40 mg QD